Controversy: PPARγ a target for treatment of colorectal cancer

Rajnish A. Gupta, Raymond N. DuBois

    Research output: Contribution to journalReview articlepeer-review

    66 Scopus citations


    Colorectal cancer (CRC) represents a significant cause of morbidity and mortality worldwide. Recently, ligands for the nuclear hormone receptor peroxisome proliferator-activated receptor γ (PPARγ) have exhibited promise in the treatment of CRC. For example, activation of PPARγ reduces the proliferation of cultured CRC cells grown in vitro or in vivo using the nude mouse xenograft model of tumor growth. Furthermore, agonists of the receptor also reduce the development of preneoplastic lesions in a model of carcinogen-induced CRC in rats. However, ligands for the receptor paradoxically enhance intestinal adenoma formation in another murine model of intestinal polyposis, the APCMin mice. These disparate results may be due to the inherent limitations of the APCMin mouse as a model for humans with CRC. Finally, genetic studies identifying loss of function mutations of PPARγ in human CRC specimens strongly suggest a tumor suppressive role for the receptor during the development of CRC.

    Original languageEnglish (US)
    Pages (from-to)G266-G269
    JournalAmerican Journal of Physiology - Gastrointestinal and Liver Physiology
    Issue number2 46-2
    StatePublished - 2002


    • Intestinal epithelial cell differentiation
    • Nuclear hormone receptor

    ASJC Scopus subject areas

    • Physiology
    • Hepatology
    • Gastroenterology
    • Physiology (medical)


    Dive into the research topics of 'Controversy: PPARγ a target for treatment of colorectal cancer'. Together they form a unique fingerprint.

    Cite this